1	Ethnic disparities in medication adherence?
2	A systematic review examining the association between ethnicity and
3	antidiabetic medication adherence
4	
5	
6	Rayah Asiri <sup>1,2¶</sup> , Adam Todd <sup>1¶</sup> , Anna Robinson <sup>1¶</sup> , Andy Husband <sup>1*¶</sup>
7	
8	
9	$^{1:}$ School of Pharmacy, Newcastle University, Newcastle upon Tyne, United Kingdom
10	<sup>2:</sup> School of Pharmacy, King Khalid University, Abha, Saudi Arabia
11	* Corresponding author:
12	E-mail: andy.husband@newcastle.ac.uk [Andy Husband]
13	
14	¶: All authors contributed equally to this work.
15	
	1

Abstract

16

17

18

19

20

21

22

23

24

25

26

27

28

29

30

31

32

33

34

35

36

37

38

**Objectives:** Adherence to prescribed medication is an essential component of diabetes management to obtain optimal outcomes. Understanding the relationship between medication adherence and ethnicity is key in optimising treatment for all people with different chronic illnesses, including those with diabetes. The aim of this review is to examine whether the adherence to antidiabetic medications differed by ethnicity among people with diabetes. **Methods:** A systematic review was conducted of studies reporting adherence to antidiabetic medication amongst people from different ethnic groups. MEDLINE, Embase, CINAHL, and PsycINFO were searched from their inception to June 2021 for quantitative studies with a specific focus on studies assessing adherence to antidiabetic medications (PROSPERO: CRD42021278392). The Joanna Briggs Institute critical appraisal checklist and a second checklist designed for studies using retrospective databases were used to assess study quality. A narrative synthesis approach was used to summarize the results based on the medication adherence measures. **Results:** Of 15,685 citations screened, 39 studies that included observational retrospective database research and cross-sectional studies were selected, each of which involved diverse ethnic groups from different settings. This review identified a difference in the adherence to antidiabetic medications by ethnicity in 37 studies, despite adjustment for several confounding variables that may otherwise explain these differences. **Conclusion:** This review revealed that adherence to antidiabetic medication differed by ethnicity. Further research is needed to explore the ethnicity-related factors that may provide an explanation for these disparities.

### Introduction

39

40

41

42

43

44

45

46

47

48

49

50

51

52

53

54

55

56

57

58

59

Diabetes is a common and clinically significant metabolic disorder, and, in recent decades, has become a major medical burden, reaching the point of a global pandemic [1, 2]. In 2019, an estimated 463 million people worldwide are thought to have diabetes [1], and this number is set to increase in the future: by 2045, the prevalence is estimated to reach 700 million globally [1, 3]. Furthermore, people with diabetes are at increased risk of developing microvascular (e.g., ischemic heart disease and cerebrovascular disease) and macrovascular complications (e.q., nephropathy and retinopathy) as well as having an increased risk of all-cause mortality [4-6]. Accordingly, glycemic control on a longterm basis is critical to diabetes management and good control has been shown to reduce diabetic complications [7, 8]. In conjunction with lifestyle management, such as diet and physical activity, improving adherence to antidiabetic medication is an important aspect of management to delay or prevent the associated complications [9]. Improving medication adherence is considered an integral part of any diabetes management plan for patients [10]. Adherence is defined as the extent to which patients follow their prescriber's instructions when taking medicines [11]. In 2003, the World Health Organization (WHO) reported that 'increasing the effectiveness of adherence interventions may have a far greater impact on the health of the population than any improvement in specific medical treatment'[12]. Improving adherence to diabetic medication is associated with improved glycemic control, reduced risk of hospitalization and mortality, as well as lower healthcare expenditure [13, 14]. There are, however, many factors that affect adherence to diabetes medication, including disease-related (e.g., the course of the illness and presence of other comorbid conditions) and treatment-related factors (complex therapy, adverse effects, and polypharmacy) [12, 15-17]. Moreover, such factors can also be influenced by information accessibility and transparency, community support, beliefs and attitudes towards a healthy lifestyle, the patient—healthcare provider relationship, mental health, and self-efficacy [18]. Furthermore, patient characteristics, such as socioeconomic background and cultural beliefs, also have potential to influence how people adhere to their medicines [12]. One such patient factor that has seldom been studied in this context is ethnicity. Given there is increased incidence of diabetes in certain ethnic groups [19], it is important to establish if, or how, adherence to diabetes medication varies by ethnic groups. This systematic review, therefore, aimed to explore whether medication adherence to antidiabetic medications in People with diabetes varied by ethnicity.

## Methods

60

61

62

63

64

65

66

67

68

69

70

71

72

75

- This systematic review was registered with PROSPERO (CRD42021278392) and conducted with the
- 73 Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines (S1
- 74 Table) [20].

## Search strategy and study selection

- 76 A systematic and comprehensive literature search was conducted in the following electronic
- databases: MEDLINE, Embase, CINAHL, and PsycINFO; from inception to June 2021. No search
- 78 restrictions were applied to the language or date of publication. Quantitative observational studies

and the quantitative sections of studies with mixed methods, examining adherence to antidiabetic medications according to ethnicity were eligible for inclusion.

- The inclusion criteria of this review were conceptualized by the PICOS (Population, Intervention, Comparison, Outcome and Study Design) framework:
  - Population: people from any ethnic groups with type 1 or type 2 diabetes mellitus.
  - Intervention: insulin and/or other antidiabetic medication, including sulfonylureas, biguanides, meglitinide, thiazolidinedione, dipeptidyl peptidase-4 inhibitors, sodium- glucose cotransporter inhibitors,  $\alpha$ -glucosidase inhibitors, and glucagon-like peptide-1 receptors agonists.
  - Comparison: people from any other ethnic groups with type 1 or type 2 diabetes mellitus.
  - Outcome: Medication adherence or persistence, measured by any medication adherence
    measure (measures based on the data of electronic databases, self-reported measures, pill
    counts, electronic monitoring, and biomedical measures), reported according to ethnicity.
  - *Study design*: quantitative observational and mixed method studies reporting on adherence by ethnicity.

The studies were required to measure adherence to antidiabetic therapy in more than one ethnic group. Any study only reporting adherence for one ethnic group only was excluded, as were studies that evaluated adherence to all medications used to control diabetes and other comorbid conditions. Qualitative studies, reviews, editorials, conference abstracts, and intervention studies were also excluded from the review.

To complement the database searches, a grey literature search was undertaken. The reference lists of all included studies were hand-searched for relevant papers not retrieved in the database search. The search strategy is described in **S1 Text**. The initial screening of titles and abstracts was undertaken by one reviewer (RA), while full-text article screening was conducted by (RA) and checked in full by (AT or AKH). Any disagreement was resolved through discussion and consensus.

### Data extraction and quality appraisal

One reviewer (RA) undertook the data extraction and was checked by another (AR). Data from each study in respect of intervention, population, outcomes, key findings, and study limitations were compiled *via* a customised data extraction form. Three reviewers (RA, AT, AKH) undertook quality assessment using two relevant tools: the Joanna Briggs Institute's critical appraisal tools for cross-sectional studies [21], and a checklist for medication adherence and persistence studies, using retrospective databases [22], as no validated quality assessment tool was suitable for all observational studies.

## **Analysis and synthesis**

Due to the heterogeneity of ethnic groups, and measures used for medication adherence across the included studies, meta-analysis to combine individual study results was not possible. A narrative synthesis approach was employed to synthesize the data [23]. The influence of ethnicity on adherence to antidiabetic therapy is described based on medication adherence measures used across the included studies: measuring adherence using electronic databases, self-reported measures, and pill counts.

# A note on reporting of the ethnicity data

While some included studies use the term 'race', we prefer the term 'ethnicity', which is defined in this review according to Senior and Bhopal 'implies one or more of the following: shared origins or social background; shared culture and traditions that are distinctive, maintained between generations, and lead to a sense of identity and group; and a common language or religious tradition [24].

Results

### Literature search and study characteristics

The initial electronic database searches identified 15,685 citations, and another 22 publications were found from reference lists, citation, and a grey literature search. Following the removal of duplicates, 15,013 studies were reviewed for eligibility based on the title and abstract; from this, 152 studies were selected for a full-text review. After full text screening, 39 studies were included in this systematic review (Fig 1).

#### Fig 1. PRISMA flow diagram of included studies

All articles were published between 2005 and 2020 and were conducted in nine countries: United States (n=25)[25-49], New Zealand (n=3) [50-52], United Kingdom (n=2)[53, 54], Canada (n=1)[55], Malaysia (n=3)[56-58], Singapore(n=2)[59, 60], Brazil (n=1)[61], Qatar (n=1)[62] and United Arab Emirates (n=1)[63]. The majority of included studies were retrospective database studies [26-29, 31-55, 57, 59, 60, 64], while the remaining were cross-sectional studies [28, 56, 58, 61-63]. The sample sizes ranged from 57[57] to 1,888,682 patients [37], and the mean age of patients ranged from 14 to 71 years. Ethnicity was reported across studies as: ethnicity in (14 studies), race/ethnicity in (15 studies), and race in (11 studies). The majority of studies examined adherence to antidiabetic medication among people with type 2 diabetes mellitus; only two studies examined adherence to antidiabetic medication adherence measures based on the electronic database data: medication possession ratio, the proportion of days covered, or other measures centred on a pharmacy database. Of the

remaining nine studies, one used pill count to measure adherence [39], while eight used self-reported measures of adherence [30, 47, 56, 58, 60-63]. Study characteristics are detailed in (Table 1).

#### Table 1. Study characteristics

Study	Country	Study Design	Data source	Population	Antidiabetic	Medication	Key finding
(author/				(number,	medication	adherence	
year)				ethnicity data)		measure	
[51]	New	Retrospective	Data collected	N= 1595	Metformin	MPR	Māori and Pasifika patients
	Zealand	database	from 10	New Zealand			had poorer metformin
			general	European.			adherence than patients of
			practices in the	Maori.			other ethnicities.
			Waikato	Asian.			After adjusted analysis, the
			region.	Pasifika.			difference remained Māori
				Others.			compared to New Zealand
							Europeans (OR 0.41; 95% CI
							0.30-0.56; P<0.001).
[35]	US	Retrospective	Data from	N= 9923	Insulin	PDC	Non-Hispanic Black (ARR,
		database	Kaiser		and/or		1.52; 95% CI, 1.32–1.74),
			Permanente	White.	OADs		Hispanic (ARR,
			Northern	Black.			
			California.				1.28; 95% CI, 1.15–1.43), and
			Camornia.	Hispanic.			Asian (ARR, 1.14; 95% CI,
				Asian.			1.01–1.29) women were
				Other.			more likely than non-
							Hispanic White women to be
							nonadherent.

[39]	US	Retrospective	Data from DPP	N=30445	Metformin	Pill count	Odds of adherence was
[55]		database	randomized clinical trial.	White. Black.		σσαπι	significantly lower for Black participants (HR 0.44; 95% CI 0.29 – 0.66; P<0.001)
				Hispanic.			compared to Whites.
				Other.			
[50]	Nave	Datasasativa	The Name	N. 00 520	Na-tfi-	MADD	After a disease for all the
[50]	New	Retrospective	The New Zealand Ministry of Health's national data collections.	N=90,530  Māori  Pacific  European  Asian  Indian  Middle  Eastern/Latin  American/African other and  Unknown	Metformin	MPR	After adjusting for all the person- and health-related factors, the annual MPR for Māori (MPR -0.08,95% CI -0.08 to 0.07) and Pacific (MPR-0.09,95% CI -0.10 to 0.08) peoples were lower than Europeans.
[56]	Malaysia	Cross- sectional	-	N=232  Malay  Chinese  Indian others	Insulin and/or OADs	Validated  Medication  Compliance  Questionnaire	Malay patients had 1.43 times higher odds of nonadherence to medications than Chinese and Indian patients (95% CI 1.32–1.74; p=0.031).

[52]	New	Retrospective	Pharmaceutical	N= 7138	OHAs	PDC	Adherence was significantly
	Zealand	database	Collection  Database  maintained by  the New  Zealand's  Ministry of  Health.	New Zealand (NZ) European. Other European NZ Māori Indian			higher in the NZ European ethnic group (PDC 64.4 vs. 9.1,20.1, and 2.8; P < 0.001).  Non-adherence was significantly higher in patients in New Zealand Māori patients (PDC 33.3 vs. 48.3,7.6, and 4.8; P < 0.001).
[36]	US	Retrospective database	Longitudinal claims data from a large US-based insurance provider	N=56720  White  Asian  Black  Hispanic	OADs	PDC	Average adherence rates of blacks and Hispanics were 4.8 to 6.5 percentage points lower than whites (p <0.01).
[58]	Malaysia	Cross- sectional	-	N= 497  Malay.  Indian.  Chinese	OADs	MMAS	There was statistically significant association between ethnicity and medication adherence (X² =10.660; P=0.031).  The Indians had higher medication adherence compared with the Malays and the Chinese
[29]	US	Retrospective database	The Veterans  Affairs  electronic	N= 148,544 White	OADs	PDC	Except for Asians, all other minorities were less likely to be adherent compared with

			health records	African American			whites (OR = 0.62; 95% CI =
			& outpatient pharmacy	Asian			0.605-0.645).
				Native American			
				Hawaiian/Pacific			
				Islander			
[65]	UK	Retrospective	Royal College	N=60327	OADs	CMG	Non-white ethnicity
		database	of General	White			associated with reduced
			Practitioners  Research and	Asian			medication persistence compared to Whites (HR
			Surveillance	Black			1.53; 95%Cl 1.47–1.59;
			Centre	Mixed			P<0.001)
			database				
				Other			
[62]	Qatar	Cross-	-	N= 260	Insulin	ARMS-D	Ethnicity was an
		sectional		Arab	and/or		independent predictor of
					OADs		adhere score (Beta -1.731;
				Asian			95% CI -3.153 – 0.309;
				Other			p=0.017). Arab ethnicity was
							likely to be non-adherent
							compared to Asian.
[28]	US	Retrospective	Administrative	N= 5163	OADs	PDC	After adjustment, Filipinos
		database	claims data	Japanese			[OR=0.58, 95%CI
		database	claims data Hawaii	Japanese			[OR=0.58, 95%CI (0.45,0.74)], Native
		database		Japanese Native Hawaiians			
		database					(0.45,0.74)], Native
		database		Native Hawaiians			(0.45,0.74)], Native Hawaiians [OR=0.74,

[60]	Singapore	Retrospective database	Public primary care clinic	Chinese  Mixed race and other race.  N= 5163  Chinese  Malay  Indian	OADs	MARS-5	were significantly less adherent to anti-diabetic medications than Japanese  Compared to Indian, patients of Chinese ethnicity (OR 2.80; 95% CI 1.53–5.15; P<0.01) had low adherence to OADs.
[57]	Malaysia	Retrospective database	Clinic Paediatric at University Kembangan Malaysia Medical Centre	Other  N=57  Malay  Chinese  Indian  Others	Insulin	MPR and glycated haemoglobin	Race was not associated with adherence(p=1.000)
[40]	US	Retrospective	Administrative claims data from a large health insurance company in Hawaii	N= 30445  Japanese.  Filipino.  Chinese.  Caucasian.  Native Hawaiian.  Other Pacific  Islander.	Insulin and/or OADs	MPR	Native Hawaiians, Other Pacific Islanders, and Filipinos had significantly lower adherence rates for each medication compared to other groups.

[59]	Singapore	Retrospective	Multicentre	N= 2463	Insulin	PDC	Indian ethnicity (OR 0.59;
		database	data of the	Chinese	and/or		95% CI 0.48–0.73; P<0.001)
			National Healthcare	Malay	OADs		was associated with poorer adherence compared with
			Group	Indian			other ethnic groups in
				Others			Singapore
[26]	US	Retrospective	Kaiser	N= 30,838	Insulin	CMG	Latinos had greater non-
		database	Permanente  Northern  California	White.  Hispanic/Latino.	and/or OADs		adherence than white patients(p<0.05)
			Diabetes Registry	African American.			
				Asian.			
[33]	US	Retrospective database	Data from Kaiser Permanente Southern California	N= 23612  Non-Hispanic  White  Black  Hispanic  Asian or Pacific  Islander  Other/Unknown	OHAs	CMG	Black race (RR 1.28;95% CI 1.17 – 1.41), Hispanic ethnicity (RR 1.11;95% CI 1.03 – 1.20) were associated with discontinuation of one or dual OHAs.
[34]	US	Retrospective database	MarketScan  Multi-State  Medicaid  Database	N= 1529 Caucasians	OADs	MPR	African Americans (OR 0.71; 95% CI 0.55–0.93; P<0.05) had significantly lower MPR than Caucasian patients.

African	
Americans	
Other races	
[61] Brazil Cross N= 1698 Insulin S	Self-reported Adherence to insulin was not
sectional	related to ethnicity.
Non-Caucasian	
[41] US Retrospective Pennsylvania N= 16,256 OHAS F	PDC Compared to perfect
database Medicaid White.	adherers, enrolees who
administrative	discontinued oral
claims data Black.	hypoglycaemics were non-
Hispanic.	white groups (43.3–57.3 %
Other/unknown.	vs. 37.3 %; P<0.0001)
[63] UAE Cross N= 446 Insulin N	MMAS Adherence levels differed
sectional Arab Emarati. and/or	significantly between ethnic
OADs Arab Non-	groups (p<0.001) with the
Emarati	lowest adherence levels for
	Emirati patients (81.6 %)
Asian.	followed by Arab Non-
	Emirati (47.1 %) and Asians
	(15.4 %).
[48] US Retrospective Group Health N= 509 Insulin N	MPR Non-Hispanic were more
database ooperative in White and/or	likely to be non-adherent to
Washington OADs	diabetes medications
State and parts African American	compared to Hispanic.
of Idaho	

				American Indian			
				/ Alaska Native.			
				Asian / Pacific			
				Islander			
				Not Hispanic			
				Hispanic			
[30]	US	Cross-	-	N= 7239	Insulin	MMAS	The White group had higher
		sectional		White	and/or		medication adherence
					antidiabetic		(50.3%; P<0.001) compared
				African American	drugs		to all groups except the
				Hispanic			American Indian group.
				Asian American			
				American Indian.			
[55]	Canada	Retrospective	Health	N=167243	Insulin	PDC	South-Asian (OR 0.44; 95% CI
		database	administrative	White	and/or		0.41–0.47; P<0.0001) and
			and pharmacy		OADs		Chinese people (OR 0.87;
			data from	South Asian			95% CI 0.82–0.93; P<0.0001)
			British	Chinese			had significantly lower
			Columbia				adherence compared with
							white people.
[45]	US	Retrospective	A Hawaiian	N=43445	Insulin	PDC	Filipinos, Native Hawaiians,
		database	health plan.	White	and/or		and other Pacific Islanders
					OADs		were significantly less
				Japanese			adherent than
				Chinese			Whites(p<0.05).

				Filipino			
				Native Hawaiian			
				Other Pacific			
				Islander			
[54]	UK	Retrospective database	Aggregated prescribing	N= 23687	OADs	MPR	There was a statistically significant variations in
			data of 76	White			adherence between the
			General	Asian			major ethnic groupings.
			Practice .	Black			(MPR range from 86.8% for
			surgeries within the	Mixed			White groups to 58.3 % for Black groups)
			Heart of	Other			
			Birmingham				
			teaching				
			Primary Care Trust				
[AC]	US	Detrochetive		N= 31636	Antidiabetic	MDD	Non White nationts (OR 1.66
[46]	US	Retrospective database	A large, Midwestern,		drugs	MPR	Non-White patients (OR 1.66 ; 95% CI 1.41 –1.95 ;
			integrated	White			P<0.001) have statistically
			health system	Black			significant lower adherence
				Asian			compared to the White
				Hispanic			
				American Indian			
[38]	US	Retrospective	Data from	N= 12,061	Antidiabetic	PDC	Patients of Hispanic ethnicity
		database	Kaiser	Non-Hispanic	drugs		(OR 1.33; 95% CI 0.84–2.10) were more likely to be
				White			were more intery to be

			Permanente	Hispanic.			primarily non-adherent
			Colorado	Other.			compared to White.
[49]	US	Retrospective	Texas Medicaid	N= 3109	OADs	MPR	Race was statistically
		database	prescription claims data	White  Black  Hispanic  Other			significantly related to adherence. The adherence was two times higher for whites compared to. Hispanics (OR 2.02; 95% CI,
[64]	US	Retrospective	The National	N= 690,968	Insulin	MPR	1.54 –2.66; P<0.0001).  Relative to non-Hispanic
		database	Patient Care &Pharmacy Benefits	NHW	and/or OHAs		whites, MPR was significantly (6.07%) lower in non-Hispanic blacks, and
			Management	Hispanic Other			(1.76%) Hispanics.
[42]	US	Retrospective database	Indiana  Network of  Patient Care	N= 3,976  White.  African American	OADs	PDC	African American race were a significant risk factor for non-adherence compared to White race (OR 0.61; 95% CI 0.50 –0.73; P<0.001)
[43]	US	Retrospective database	Veterans Administration datasets	N= 11,272  NHW  NHB  Hispanic	Insulin and/or OHAs	MPR	NHB had statistically significantly lower MPR compared to NHW.

				Other			
[47]	US	Retrospective database	Two primary care clinics and two diabetes	N= 383 White	Antidiabetic drugs	SDSCA questionnaire	African American race was significantly associated with less medication adherence
			specialty clinics	African American			(r=-0.10, p<0.05)
[37]	US	Retrospective database	Administrative claims data primarily	N= 1,888,682 White	OHAs	PDC	Black (OR 1.39; 95% CI 1.38 –  1.41; P<0.001) and Hispanic  patients (OR 1.37; 95% CI
			pharmacy	Black			1.35–1.39; P<0.001) more
			claims data	Hispanic Others			likely than whites to be nonadherent.
[27]	US	Retrospective	Harvard	N= 1906	Insulin	Monthly	Blacks had statistically
		database	Vanguard Medical Associates electronic medical record system	Black White	and/or OADs	average rate of adherence	significantly lower MPR compared to Whites (IRR 079; 95% CI 0.63–0.99; P<0.05).
[31]	US	Retrospective database	Harvard Vanguard Medical Associates	N= 1806  Black  White	OADs	Refill-based medication adherence	Black patients had a significant lower average of medication adherence compared to whites. (71.7% vs. 77.6%; P<0.0001)
[44]	US	Retrospective database	Data from the  North Carolina	N= 17,685	OADs	MPR	The adherence rate of African American patients

			Medicaid	African			was significantly lower by
			program	American.			12% than whites (p<0.05)
				White			
[32]	US	Retrospective	A large health	N= 20685	OADs	MPR	Compared to Whites,
		database	care plan in Hawaii	Japanese Chinese			Japanese patients (OR 1.20;
							95% CI 1.0 –1.30) were the
							most likely to be adherent,
				Whites			followed by Chinese (OR 1.0
				Hawaiians			95% CI 0.89 –1.20),
							Hawaiians (OR 0.89; 95% CI
				Filipinos			0.77 –1.0), and Filipinos (OR
				other			0.78; 95% CI 0.68 –0.90)

MPR: medication possession ratio, PDC: proportion of days covered, MMAS: Morisky Medication Adherence Scale, CMG: continuous single-interval measure of medication gaps, ARMS-D: Adherence to Refill and Medications Scale in Diabetes, MARS-5: five-question Medication Adherence Rating Scale, SDSCA: the Summary of Diabetes Self-Care Activities questionnaire, OHAs: oral hypoglycaemic agents, OADs: oral antidiabetic drugs ,NHW: Non-Hispanic Whites, NHB: Non-Hispanic Blacks, US: United State, UK: United Kingdom, OR: odd ratio, CI: confidence interval, ARR: adjusted risk ratio, P: p value, HR: hazard ratio, RR: relative risk, r:correlation coefficient, IRR: incidence rate ratio.

# **Quality assessment**

Two quality assessment tools were used in this review based on the study design. The first tool, a checklist for medication adherence and persistence studies using retrospective databases, was used for the 33 retrospective database studies [22]. All study titles were descriptive and reflective of the study purpose, and all abstracts provided a short description of the work. The rationale and scientific background were reported in most studies except for five, which did not clearly state their objectives [26, 35, 42, 45, 57]. Most of the articles clearly stated the study design that matched the objectives;

only eight did not do so [36, 40, 47, 50-52, 54, 60] . The data sources were clearly defined in all studies; however, three papers did not state the time frame for data [26, 47, 59] . Of the 33 studies, 29 clearly stated the eligibility criteria, but 16 did not explain the rationale for these criteria [26, 28, 34, 39, 45, 47-49, 51, 52, 54, 55, 57, 60, 64] . The method of medication adherence measurement was clearly described in the majority of studies, but, for some studies, the method of handling the switching of drugs within and between therapeutic classes was not appropriately explained [26, 27, 34, 38, 42-46, 48, 49, 52, 54, 55, 59, 60]. All studies apart from three [40, 41, 52], controlled the confounders, while all studies clearly presented their results and discussed the research implications (S2 Table).

The quality of the six remaining cross-sectional studies was assessed using the Joanna Briggs Institute's critical appraisal tools for cross-sectional studies [21]. All studies clearly defined the inclusion criteria, study subjects, and settings, but two did not report on strategies to deal with confounding factors [30, 58]. All studies, but one, used a valid and reliable measure of medication adherence [61] (S3 Table).

Narrative synthesis of the influence of ethnicity on adherence to

## antidiabetic medication by method of measurement

Studies were described below thematically according to medication adherence measures using a narrative synthesis approach [23].

#### Studies measured adherence using electronic databases

A variety of measures using pharmacy refill data were used to assess adherence to antidiabetic medications among different ethnic groups, including the MPR[28, 34, 40, 43, 44, 46, 48-51, 54, 57, 60, 64], proportion of days covered[29, 35-38, 41, 42, 45, 52, 55, 59], and other measures, such as

medication refill adherence and continuous single- or multiple-interval measures of medication gaps[26, 27, 31, 33, 53].

193

194

195

196

197

198

199

200

201

202

203

204

205

206

207

208

209

210

211

212

213

214

215

216

217

218

219

220

Medication possession ratio: Fourteen studies used the MPR to evaluate medication adherence for people with diabetes from different ethnic groups. Three studies assessed adherence to antidiabetic medications among the following ethnic groups: Japanese, Hawaiians, Whites, Filipinos, Chinese, mixed races, and other races [28, 40, 60]. The reported adherence rates varied by ethnicity with people of Japanese ethnicity most likely to be adherent to antidiabetic medications, followed by Whites, Chinese, Hawaiians, Filipinos, and other ethnic groups; this difference was statistically significant in two studies [28, 60]. The difference between people from the following ethnicities: Whites, African Americans, Hispanics, Asians, American Indians, and others in adherence to antidiabetic medications was also reported in seven studies [34, 43, 44, 46, 48, 49, 64]. People with a Non-White ethnicity had a statistically significant lower MPR compared to people with White ethnicity across these studies. Two other studies examined adherence to metformin among ethnic groups in New Zealand and revealed that people from Māori and Pacific ethnic groups had poorer adherence than people from the European group [50, 51]. Langley and colleagues also reported statistically significant variations in adherence to oral antidiabetic medications among different ethnic groups in the United Kingdom, with highest adherence rates reported for people from Irish ethnic groups, while lowest adherence rates were reported for people from African ethnic groups [54]. Only one study assessed adherence to insulin therapy for type 1 diabetes; across three Asian ethnic groups – Malay, Chinese, and Indian – ethnicity was not associated with adherence [57].

**Proportion of days covered:** Eleven studies used the proportion of days covered to assess adherence to antidiabetic medications by people of different ethnic groups. Of these, seven studies indicated that people from Black, Hispanic, and Asian ethnicity were more likely to be non-adherent to antidiabetic medications, and these findings were statistically significant in four studies [35-38, 41, 42]. The adherence levels also differed among people with White, Chinese, Black, Hawaiian, Japanese, Filipino, and Native American ethnicities [29, 45, 55]. In contrast to the studies using the

MPR, one study found that the medication adherence of people from Chinese and Japanese ethnic groups did not differ significantly from people from White ethnicity; however, members of other ethnic groups were found to be significantly less adherent compared to people from White ethnic groups[45]. Additionally, significant differences in adherence to antidiabetic agents were reported among three Asian ethnic groups in a study conducted in Singapore, in which people from Indian ethnic groups had the lowest adherence rates compared to people from Malay or Chinese ethnic groups [59]. Lastly, Kharjul and colleagues reported a significantly higher rate of non-adherence among people from Māori ethnicity compared to other ethnic groups in New Zealand, which is consistent with the findings of studies assessing the same groups, using the MPR as a measure of adherence [52].

Other measures (medication refill adherence and continuous single- or multiple-interval measures of medication gaps): Two studies, estimating adherence based on pharmacy refill data, reported a statistically significant difference in adherence to antidiabetic medication between people from Black and White ethnicities [27, 31]. Medication persistence was also assessed in three studies of different ethnic groups using a continuous single-interval measure of medication gaps. These studies showed that non-White ethnicity was associated with lower medication persistence when compared to White ethnicity [26, 33, 53].

#### Study measured adherence using pill count

Walker and colleagues used pill counts to assess adherence to metformin for three ethnic groups: Whites, Blacks, and Hispanics. The authors found that metformin adherence varied significantly by ethnicity, and the odds of adherence were lower for people with Black ethnicity [39].

#### Studies measured adherence using self-report measures of adherence

Eight studies assessed adherence to antidiabetic medications using a variety of self-report measures, including the five-question Medication Adherence Rating Scale [60], Morisky Medication Adherence Scale [30, 58, 63], validated Medication Compliance Questionnaire [56], Adherence to Refill and Medications Scale in Diabetes [62], medication adherence subscale of the Summary of Diabetes Self-Care Activities questionnaire [47], and self-reported scales [61]. In three of these studies, statistically significant differences in adherence were found among three Asian ethnic groups: Chinese, Malays, and Indians [56, 58, 60]. Lopez and colleagues [30] and Osborn and colleagues [47] demonstrated a significant association between increased adherence to antidiabetic medications and White ethnicity compared to other ethnic groups [30, 47]. A study conducted in the United Arab Emirates also reported significant variation in adherence levels to antidiabetic medications among three ethnic groups (Arabs of the United Arab Emirates, Arabs non-Emirate, and Asians) with the highest level of adherence reported for people with Asian ethnicity and the lowest for people with Arab ethnic groups [63]. The findings of this study are consistent with another study conducted in Qatar, in which people with diabetes of Arab ethnicity were more likely to be non-adherent to their medication compared to people from Asian ethnicity [62]. Only one study found that adherence to antidiabetic medications did not differ by ethnicity in people with type 1 diabetes [61].

### Discussion

246

247

248

249

250

251

252

253

254

255

256

257

258

259

260

261

262

263

264

265

266

267

268

269

270

271

272

This systematic review aimed to examine the association between ethnicity and adherence to antidiabetic medications in people with type 1 and type 2 diabetes mellitus. This review identified several studies showing that adherence to antidiabetic medications varied according to the ethnic groups. This variation was statistically significant in 23 studies of 39 included studies and was observed when adherence was measured using various measurements methods. The finding of this review supports the work of Peeters and colleagues who reported a direct association between ethnicity and adherence across three studies [18]. This work, however, only focused on oral hypoglycemic medications in type 2 diabetes, and was published in 2011 (and since this time more

relevant literature has been published)[18]. Taken together, these findings may help explain some of the ethnic/racial disparities in diabetes outcomes[66-68], as optimum glycemic control is one of the major factors influencing diabetes outcome[69]. Nonetheless, these findings also offer a strong foundation for exploring the ethnicity-related factors that might explain the differences in adherence to antidiabetic medications. Understanding the possible reasons why these differences occur amongst minority ethnic groups will help develop interventions tailored to patients in ethnically diverse populations. Given the emphasis of previous literature emphasizing the need to understand patient-specific factors to design effective adherence interventions, the findings of this work are even more relevant for future research [70].

One interesting finding of this review is that most studies reported statistically significant differences in adherence to antidiabetic medications after controlling for different confounders (e.g., socioeconomic variables) mediating the association between ethnicity and adherence to antidiabetic medications. However, the ethnicity—adherence association in some studies could be attributed to socioeconomic differences among ethnic groups, or other uncontrolled confounders, such as clinical, demographic, and psychological factors, which could mediate the ethnicity- adherence association. In accordance with the present results, one previous study demonstrated that improved health literacy diminished the ethnic differences in adherence to antidiabetic medications [47].

A possible explanation for the differences in adherences to antidiabetic medications among different ethnic groups after controlling confounders mediating adherence-ethnicity associations is related to the socio-cultural background and patients' beliefs and perceptions about treatment, which was shown in a systematic review of 25 cross-sectional studies to be significantly associated with medication adherence in patients with type2 diabetes, asthma, and hypertension [71]. The association may also be explained by the findings reported in several qualitative studies of the barriers of nonadherence to antidiabetic medications and diabetes self-management in some ethnic groups. For example, social stigma and cultural pressure associated with diabetes in people from South Asian background as a barrier for diabetes management [72], the preference of traditional medicines over the use of metformin in people from Māori ethnicity as a cause for suboptimal adherence [73] and feeling frustrated and fearful about taking medicines lifelong in people from

African American ethnicity as a reason for nonadherence[74], are all possible explanations of the disparities. Future work could examine the socio-cultural factors affecting adherence to antidiabetic medications for different ethnic groups.

This review has some limitations. Firstly, it is important to acknowledge the diversity among included studies regarding the settings, designs, measurements of adherence to antidiabetic medications, and inconsistency in reporting ethnicity data. It is therefore not possible to compare across included studies to determine which ethnic group is the most adherent in the context of diabetes management. Secondly, there is no validated quality assessment tool for all observational studies, including retrospective database observational studies and cross-sectional studies. Consequently, using two critical appraisal tools does not allow for a comparison of quality across all studies. Lastly, the included studies primarily used self-reported measures or pharmacy claims data to assess adherence, leading to overestimating adherence or failing to reflect the actual medication-taking behaviour [75]. Notwithstanding these limitations, the results of this review have important implications for optimizing adherence to antidiabetic medications among different ethnic groups. Additionally, the large number of studies that met the eligibility criteria included in this review by using search strategies include broad terms with no restrictions on publication date or language, and an additional grey literature search complemented the original canvass, ensuring the inclusion of all relevant studies (S1 Text).

# Conclusion

This systematic review is one of the first to examine the association between ethnicity and medication adherence in people with type 1 and type 2 diabetes mellitus. The findings show difference among diverse ethnic groups regarding adherence to antidiabetic medications, and these differences persist after controlling for several different demographic, clinical, socioeconomic, and psychological factors. Future research should therefore focus on explaining and understanding why these disparities occur amongst ethnic groups. Understanding the reasons behind these disparities

328

329

330

331

332

333

334

335

336

337

338

339

340

341

342

343

344

345

346

347

348

349

will have important implications for the future care of people with diabetes, including developing possible patient-centred interventions for optimizing adherence to diabetic therapy. References 1. Guariguata L, Whiting DR, Hambleton I, Beagley J, Linnenkamp U, Shaw JE. Global estimates of diabetes prevalence for 2013 and projections for 2035. Diabetes Res Clin Pract. 2014;103(2):137-49. 2. Lin X, Xu Y, Pan X, Xu J, Ding Y, Sun X, et al. Global, regional, and national burden and trend of diabetes in 195 countries and territories: an analysis from 1990 to 2025. Sci Rep. 2020;10(1):14790. 3. Saeedi P, Petersohn I, Salpea P, Malanda B, Karuranga S, Unwin N, et al. Global and regional diabetes prevalence estimates for 2019 and projections for 2030 and 2045: Results from the International Diabetes Federation Diabetes Atlas, 9(th) edition. Diabetes Res Clin Pract. 2019;157:107843. 4. Collaboration ERF. Diabetes mellitus, fasting glucose, and risk of cause-specific death. New England Journal of Medicine. 2011;364(9):829-41. 5. Gregg EW, Gu Q, Cheng YJ, Narayan KM, Cowie CC. Mortality trends in men and women with diabetes, 1971 to 2000. Ann Intern Med. 2007;147(3):149-55. 6. Lind M, Garcia-Rodriguez L, Booth G, Cea-Soriano L, Shah B, Ekeroth G, et al. Mortality trends in patients with and without diabetes in Ontario, Canada and the UK from 1996 to 2009: a population-based study. Diabetologia. 2013;56(12):2601-8. Asche C, LaFleur J, Conner C. A review of diabetes treatment adherence and the association with clinical and economic outcomes. Clin Ther. 2011;33(1):74-109.

- 350 8. Zoungas S, Chalmers J, Ninomiya T, Li Q, Cooper M, Colagiuri S, et al. Association of HbA 1c levels with vascular
- 351 complications and death in patients with type 2 diabetes: evidence of glycaemic thresholds. Diabetologia.
- **352** 2012;55(3):636-43.
- Inzucchi SE, Bergenstal RM, Buse JB, Diamant M, Ferrannini E, Nauck M, et al. Management of hyperglycemia in
- 354 type 2 diabetes: a patient-centered approach: position statement of the American Diabetes Association (ADA) and the
- European Association for the Study of Diabetes (EASD). Diabetes Spectrum. 2012;25(3):154-71.
- 356 10. Pladevall M, Williams LK, Potts LA, Divine G, Xi H, Lafata JE. Clinical outcomes and adherence to medications
- measured by claims data in patients with diabetes. Diabetes Care. 2004;27(12):2800-5.
- Vrijens B, De Geest S, Hughes DA, Przemysław K, Demonceau J, Ruppar T, et al. A new taxonomy for describing
- and defining adherence to medications. British journal of clinical pharmacology. 2012;73(5):691-705.
- 360 12. De Geest S, Sabate E. Adherence to long-term therapies: evidence for action. Eur J Cardiovasc Nurs.
- 361 2003;2(4):323.
- 362 13. Ho PM, Rumsfeld JS, Masoudi FA, McClure DL, Plomondon ME, Steiner JF, et al. Effect of medication
- 363 nonadherence on hospitalization and mortality among patients with diabetes mellitus. Arch Intern Med.
- 364 2006;166(17):1836-41.
- Rhee MK, Slocum W, Ziemer DC, Culler SD, Cook CB, El-Kebbi IM, et al. Patient adherence improves glycemic
- 366 control. The Diabetes Educator. 2005;31(2):240-50.
- 367 15. Brown MT, Bussell JK. Medication adherence: WHO cares? Mayo Clin Proc. 2011;86(4):304-14.
- Rubin RR. Adherence to pharmacologic therapy in patients with type 2 diabetes mellitus. Am J Med. 2005;118
- 369 Suppl 5A(5):27S-34S.
- 370 17. Grant RW, Devita NG, Singer DE, Meigs JB. Polypharmacy and medication adherence in patients with type 2
- 371 diabetes. Diabetes Care. 2003;26(5):1408-12.

- Peeters B, Van Tongelen I, Boussery K, Mehuys E, Remon JP, Willems S. Factors associated with medication
- adherence to oral hypoglycaemic agents in different ethnic groups suffering from type 2 diabetes: a systematic literature
- review and suggestions for further research. Diabetic Medicine. 2011;28(3):262-75.
- 375 19. Spanakis EK, Golden SH. Race/ethnic difference in diabetes and diabetic complications. Current diabetes reports.
- **376** 2013;13(6):814-23.
- Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, et al. The PRISMA 2020 statement: An
- updated guideline for reporting systematic reviews. Int J Surg. 2021;88:105906.
- 379 21. Institute JB. The Joanna Briggs Institute Critical Appraisal Tools for Use in JBI Systematic Reviews Checklist for
- Analytical Cross Sectional Studies. North Adelaide, Australia The Joanna Briggs Institute. 2017.
- Peterson AM, Nau DP, Cramer JA, Benner J, Gwadry-Sridhar F, Nichol M. A checklist for medication compliance
- and persistence studies using retrospective databases. Value in health. 2007;10(1):3-12.
- Popay J, Roberts H, Sowden A, Petticrew M, Arai L, Rodgers M, et al. Guidance on the conduct of narrative
- synthesis in systematic reviews. A product from the ESRC methods programme Version. 2006;1:b92.
- Senior PA, Bhopal R. Ethnicity as a variable in epidemiological research. Bmj. 1994;309(6950):327-30.
- 386 25. Egede LE, Gebregziabher M, Hunt KJ, Axon RN, Echols C, Gilbert GE, et al. Regional, geographic, and ethnic
- differences in medication adherence among adults with type 2 diabetes. Annals of Pharmacotherapy. 2011;45(2):169-78.
- Fernandez A, Quan J, Moffet H, Parker MM, Schillinger D, Karter AJ. Adherence to Newly Prescribed Diabetes
- Medications Among Insured Latino and White Patients With Diabetes. JAMA Intern Med. 2017;177(3):371-9.
- 390 27. Trinacty CM, Adams AS, Soumerai SB, Zhang F, Meigs JB, Piette JD, et al. Racial differences in long-term
- adherence to oral antidiabetic drug therapy: a longitudinal cohort study. BMC Health Serv Res. 2009;9:24.
- Taira DA, Seto BK, Davis JW, Seto TB, Landsittel D, Sumida WK. Examining Factors Associated With Nonadherence
- And Identifying Providers Caring For Nonadherent Subgroups. J Pharm Health Serv Res. 2017;8(4):247-53.

- 394 29. Gatwood JD, Chisholm-Burns M, Davis R, Thomas F, Potukuchi P, Hung A, et al. Disparities in initial oral
- antidiabetic medication adherence among veterans with incident diabetes. Journal of managed care & specialty
- 396 pharmacy. 2018;24(4):379-89.
- 397 30. Lopez JM, Bailey RA, Rupnow MF, Annunziata K. Characterization of type 2 diabetes mellitus burden by age and
- ethnic groups based on a nationwide survey. Clin Ther. 2014;36(4):494-506.
- 399 31. Adams AS, Trinacty CM, Zhang F, Kleinman K, Grant RW, Meigs JB, et al. Medication adherence and racial
- differences in A1C control. Diabetes Care. 2008;31(5):916-21.
- 401 32. Lee R, Taira DA. PEER REVIEWED: Adherence to Oral Hypoglycemic Agents in Hawaii. Preventing chronic disease.
- 402 2005;2(2).
- 403 33. Reynolds K, An J, Wu J, Harrison TN, Wei R, Stuart B, et al. Treatment discontinuation of oral hypoglycemic agents
- and healthcare utilization among patients with diabetes. Journal of Diabetes and its Complications. 2016;30(8):1443-51.
- 405 34. Patel I, Erickson SR, Caldwell CH, Woolford SJ, Bagozzi RP, Chang J, et al. Predictors of medication adherence and
- persistence in Medicaid enrollees with developmental disabilities and type 2 diabetes. Res Social Adm Pharm.
- 407 2016;12(4):592-603.
- 408 35. Marshall CJ, Rodriguez HP, Dyer W, Schmittdiel JA. Racial and ethnic disparities in diabetes care quality among
- women of reproductive age in an integrated delivery system. Women's Health Issues. 2020;30(3):191-9.
- 410 36. Xie Z, St. Clair P, Goldman DP, Joyce G. Racial and ethnic disparities in medication adherence among privately
- insured patients in the United States. PLoS One. 2019;14(2):e0212117.
- 412 37. Yang Y, Thumula V, Pace PF, Banahan III BF, Wilkin NE, Lobb WB. Predictors of medication nonadherence among
- 413 patients with diabetes in Medicare Part D programs: a retrospective cohort study. Clinical therapeutics.
- 414 2009;31(10):2178-88.
- 415 38. Raebel MA, Ellis JL, Carroll NM, Bayliss EA, McGinnis B, Schroeder EB, et al. Characteristics of patients with
- primary non-adherence to medications for hypertension, diabetes, and lipid disorders. J Gen Intern Med. 2012;27(1):57-
- **417** 64.

- 418 39. Walker EA, Gonzalez JS, Tripputi MT, Dagogo-Jack S, Matulik MJ, Montez MG, et al. Long-term metformin
- adherence in the Diabetes Prevention Program Outcomes Study. BMJ Open Diabetes Res Care. 2020;8(1):e001537.
- 420 40. Sutton CX, Carpenter D-A, Sumida W, Taira D. 2016 Writing Contest Undergraduate Winner: The Relationship
- Between Medication Adherence and Total Healthcare Expenditures by Race/Ethnicity in Patients with Diabetes in Hawai
- 422 'i. Hawai'i Journal of Medicine & Public Health. 2017;76(7):183.
- 423 41. Lo-Ciganic WH, Donohue JM, Jones BL, Perera S, Thorpe JM, Thorpe CT, et al. Trajectories of Diabetes Medication
- 424 Adherence and Hospitalization Risk: A Retrospective Cohort Study in a Large State Medicaid Program. J Gen Intern Med.
- 425 2016;31(9):1052-60.
- 426 42. Zhu VJ, Tu W, Marrero DG, Rosenman MB, Overhage JM, editors. Race and medication adherence and glycemic
- 427 control: findings from an operational health information exchange. AMIA Annual Symposium Proceedings; 2011:
- 428 American Medical Informatics Association.
- 429 43. Gebregziabher M, Lynch CP, Mueller M, Gilbert GE, Echols C, Zhao Y, et al. Using quantile regression to
- investigate racial disparities in medication non-adherence. BMC medical research methodology. 2011;11(1):1-11.
- 431 44. Shenolikar RA, Balkrishnan R, Camacho FT, Whitmire JT, Anderson RT. Race and medication adherence in
- 432 Medicaid enrollees with type-2 diabetes. J Natl Med Assoc. 2006;98(7):1071-7.
- 433 45. Juarez DT, Tan C, Davis JW, Mau MM. Using quantile regression to assess disparities in medication adherence.
- 434 American journal of health behavior. 2014;38(1):53-62.
- 435 46. Rolnick SJ, Pawloski PA, Hedblom BD, Asche SE, Bruzek RJ. Patient characteristics associated with medication
- 436 adherence. Clin Med Res. 2013;11(2):54-65.
- 437 47. Osborn CY, Cavanaugh K, Wallston KA, Kripalani S, Elasy TA, Rothman RL, et al. Health literacy explains racial
- disparities in diabetes medication adherence. J Health Commun. 2011;16 Suppl 3(sup3):268-78.
- 439 48. Calip GS, Hubbard RA, Stergachis A, Malone KE, Gralow JR, Boudreau DM. Adherence to oral diabetes
- 440 medications and glycemic control during and following breast cancer treatment. Pharmacoepidemiol Drug Saf.
- **441** 2015;24(1):75-85.

- 442 49. Adeyemi AO, Rascati KL, Lawson KA, Strassels SA. Adherence to oral antidiabetic medications in the pediatric
- population with type 2 diabetes: a retrospective database analysis. Clin Ther. 2012;34(3):712-9.
- Horsburgh S, Barson D, Zeng J, Sharples K, Parkin L. Adherence to metformin monotherapy in people with type
- 2 diabetes mellitus in New Zealand. Diabetes Res Clin Pract. 2019;158:107902.
- Chepulis L, Mayo C, Morison B, Keenan R, Lao C, Paul R, et al. Metformin adherence in patients with type 2
- diabetes and its association with glycated haemoglobin levels. J Prim Health Care. 2020;12(4):318-26.
- Kharjul MD, Cameron C, Braund R. Using the Pharmaceutical Collection Database to identify patient adherence
- to oral hypoglycaemic medicines. Journal of primary health care. 2019;11(3):265-74.
- 450 53. McGovern A, Tippu Z, Hinton W, Munro N, Whyte M, de Lusignan S. Comparison of medication adherence and
- persistence in type 2 diabetes: A systematic review and meta-analysis. Diabetes, Obesity & Metabolism.20(4):1040-3.
- 452 54. Langley CA, Bush J. The Aston Medication Adherence Study: mapping the adherence patterns of an inner-city
- 453 population. Int J Clin Pharm. 2014;36(1):202-11.
- 454 55. Chong E, Wang H, King-Shier K, Quan H, Rabi D, Khan N. Prescribing patterns and adherence to medication
- among South-Asian, Chinese and white people with Type 2 diabetes mellitus: a population-based cohort study. Diabetic
- 456 medicine. 2014;31(12):1586-93.
- 457 56. Abdullah NF, Khuan L, Theng CA, Sowtali SN, Juni MH. Effect of patient characteristics on medication adherence
- among patients with type 2 diabetes mellitus: a cross-sectional survey. Contemporary nurse. 2019;55(1):27-37.
- 459 57. Ying C, Shah N. Adherence to insulin treatment in children with type I diabetes mellitus at a hospital in Malaysia.
- 460 Asian J Pharm Clin Res. 2017;10:356-61.
- Jannoo Z, Khan NM. Medication adherence and diabetes self-care activities among patients with type 2 diabetes
- mellitus. Value in health regional issues. 2019;18:30-5.
- 463 59. Lin L-K, Sun Y, Heng BH, Chew DEK, Chong P-N. Medication adherence and glycemic control among newly
- diagnosed diabetes patients. BMJ Open Diabetes Research and Care. 2017;5(1):e000429.

- 465 60. Lee CS, Tan JHM, Sankari U, Koh YLE, Tan NC. Assessing oral medication adherence among patients with type 2
- diabetes mellitus treated with polytherapy in a developed Asian community: a cross-sectional study. BMJ open.
- 467 2017;7(9):e016317.
- 468 61. Gomes MB, Negrato CA. Adherence to insulin therapeutic regimens in patients with type 1 diabetes. A
- nationwide survey in Brazil. Diabetes Res Clin Pract. 2016;120:47-55.
- 470 62. Jaam M, Mohamed Ibrahim MI, Kheir N, Hadi MA, Diab MI, Awaisu A. Assessing prevalence of and barriers to
- 471 medication adherence in patients with uncontrolled diabetes attending primary healthcare clinics in Qatar. Prim Care
- 472 Diabetes. 2018;12(2):116-25.
- 473 63. Mohd MMA-H, Phung H, Sun J, Morisky DE. The predictors to medication adherence among adults with diabetes
- in the United Arab Emirates. Journal of Diabetes & Metabolic Disorders. 2015;15(1):1-9.
- 475 64. Egede LE, Gebregziabher M, Hunt KJ, Axon RN, Echols C, Gilbert GE, et al. Regional, Geographic, and Ethnic
- Differences in Medication Adherence Among Adults with Type 2 Diabetes. Ann Pharmacother. 2011;45(2):169-78.
- 477 65. McGovern A, Hinton W, Calderara S, Munro N, Whyte M, de Lusignan S. A Class Comparison of Medication
- Persistence in People with Type 2 Diabetes: A Retrospective Observational Study. Diabetes Ther. 2018;9(1):229-42.
- 479 66. Goff LM. Ethnicity and Type 2 diabetes in the UK. Diabet Med. 2019;36(8):927-38.
- 480 67. Andersen JA, Scoggins D, Michaud T, Wan N, Wen M, Su D. Racial Disparities in Diabetes Management Outcomes:
- Evidence from a Remote Patient Monitoring Program for Type 2 Diabetic Patients. Telemed J E Health. 2021;27(1):55-61.
- 482 68. Haw JS, Shah M, Turbow S, Egeolu M, Umpierrez G. Diabetes Complications in Racial and Ethnic Minority
- 483 Populations in the USA. Curr Diab Rep. 2021;21(1):2.
- 484 69. Khunti N, Khunti N, Khunti K. Adherence to type 2 diabetes management. British Journal of Diabetes.
- 485 2019;19(2):99-104.
- Williams JL, Walker RJ, Smalls BL, Campbell JA, Egede LE. Effective interventions to improve medication
- adherence in Type 2 diabetes: a systematic review. Diabetes Manag (Lond). 2014;4(1):29-48.

488 71. Shahin W, Kennedy GA, Stupans I. The impact of personal and cultural beliefs on medication adherence of 489 patients with chronic illnesses: a systematic review. Patient Prefer Adherence. 2019;13:1019-35. 490 72. Singh H, Cinnirella M, Bradley C. Support systems for and barriers to diabetes management in South Asians and 491 Whites in the UK: qualitative study of patients' perspectives. BMJ Open. 2012;2(6):e001459. 492 73. Parkin L, Maclennan K, Te Morenga L, Inder M, Moata'ane L. What helps and hinders metformin adherence and 493 persistence? A qualitative study exploring the views of people with type 2 diabetes. The New Zealand Medical Journal 494 (Online). 2021;134(1536):25-40. 495 74. Shiyanbola OO, Brown CM, Ward EC. "I did not want to take that medicine": African-Americans' reasons for 496 diabetes medication nonadherence and perceived solutions for enhancing adherence. Patient preference and adherence. 497 2018;12:409. 498 75. Anghel LA, Farcas AM, Oprean RN. An overview of the common methods used to measure treatment adherence. 499 Medicine and pharmacy reports. 2019;92(2):117. 500 501 Supporting information 502 503 S1 Table. PRISMA 2020 checklist 504 \$1 Text. Database search terms 505 <u>S2 Table.</u> Results of the risk of bias assessment of retrospective database studies S3 Table. Results of the risk of bias assessment of cross-sectional studies 506 507 S4 Table. Data extraction form

